

Obestatin for use as antineoplastic agent in the treatment of pancreatic cancer



Business area

Discovery

Market sector

Antineoplastic drugs

Medical Indication

Pancreatic cancer treatment

Research goal

The present invention refers to the use of obestatin as antineoplastic agent in the treatment of pancreatic cancer.

Problem to solve

While pancreatic cancer survival rates have been improving from decade to decade, the disease is still considered largely incurable. According to the American Cancer Society, for all stages of pancreatic cancer combined, the five-year rate is 12%. One of the major restraints of the pancreatic cancer drugs market is the inadequacy of results given by the drugs at the time of treatment. This fact is due to the aggressive nature of pancreatic cancer as the cancer cells spread throughout the body in a short period. The late discovery of pancreatic cancer affects the efficacy of the drugs because the drugs can work effectively only if cancer is detected timely in an early stage itself (in stage 1 or stage 2, where cancer cells are limited to where the tumor is present). Therefore, the mortality rate for pancreatic cancer is very high.

Innovation

The concept of combination therapy over monotherapy is one of the latest ongoing trends in the pancreatic cancer drugs market. Major players in the market understand that the combination of two or more drugs is a suitable way to increase the efficacy of the drugs and thus increase the rate of survival of patients being diagnosed with pancreatic cancer. However, the chemotherapy toxicities in these aggressive managements of pancreatic cancer can also impact patient survival.

Among the reasons for the lethality of pancreatic cancer, late diagnosis and resistance to chemotherapy play a key role. The main factor contributing to resistance is the presence of a poorly vascularized and compact stroma, which acts as a barrier to drug delivery.

In this scenario, the present invention is focused on solving the above cited problem and provides a new treatment aimed at inhibiting tumor growth, directly or indirectly, through the remodeling of parameters associated with the tumor microenvironment.

Market opportunity

The global pancreatic cancer drugs market will grow from \$3.72 billion in 2022 to \$3.91 billion in 2023 at a compound annual growth rate (CAGR) of 5.0%. The pancreatic cancer drugs market is expected to grow to \$4.60 billion in 2027 at a CAGR of 4.1%. The increasing prevalence of pancreatic cancer is expected to drive the growth of the pancreatic cancer drug market. With the rise in several pancreatic cancer cases, the demand for drugs is expected to increase as well, which will drive the growth of the market.

Research team


Digestive Pathology and Cellular Endocrinology Research Groups of the Health Research Institute of Santiago de Compostela

- **Jesús Pérez Camiña**
- **Tania Cid Díaz**
- **Saúl Leal López**
- **Yolanda Pazos Randulfe**
- **Icía Santos Zas**
- **Andrea Calviño Lodeiro**
- **J. Enrique Domínguez Muñoz**

Intellectual property

European patent application, number **EP23382269**
"Obestatin for use as antineoplastic agent in the treatment of pancreatic cancer"

Development stage:



Available for: *Licensing, co-development*